BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2025
BIOQUAL, Inc. (OTC Pink: BIOQ) has released its unaudited financial results for the first quarter of fiscal year 2025, ending August 31, 2024. The company reported a significant decline in performance compared to the same period last year:
- Revenue decreased to $11,770,482 from $15,578,922 in Q1 FY2024
- Income before income tax shifted to a loss of $931,825 from a profit of $1,241,183
- Net income turned to a loss of $675,325 from a profit of $899,483
- Basic and diluted earnings per share of common stock dropped to ($0.76) from $1.01
The weighted average number of shares outstanding remained stable at 894,416 for basic earnings per share and 894,405 for diluted earnings per share.
BIOQUAL, Inc. (OTC Pink: BIOQ) ha pubblicato i suoi risultati finanziari non revisionati per il primo trimestre dell'anno fiscale 2025, terminato il 31 agosto 2024. L'azienda ha registrato un significativo calo delle performance rispetto allo stesso periodo dell'anno scorso:
- I ricavi sono diminuiti a $11.770.482 rispetto a $15.578.922 nel Q1 FY2024
- Il reddito prima delle imposte sul reddito è passato a una perdita di $931.825 rispetto a un profitto di $1.241.183
- Il reddito netto si è trasformato in una perdita di $675.325 rispetto a un profitto di $899.483
- Gli utili per azione di base e diluiti delle azioni ordinarie sono scesi a ($0.76) rispetto a $1.01
Il numero medio ponderato di azioni in circolazione è rimasto stabile a 894.416 per gli utili per azione di base e 894.405 per gli utili per azione diluiti.
BIOQUAL, Inc. (OTC Pink: BIOQ) ha publicado sus resultados financieros no auditados para el primer trimestre del año fiscal 2025, finalizado el 31 de agosto de 2024. La compañía reportó una disminución significativa en su rendimiento en comparación con el mismo período del año pasado:
- Los ingresos disminuyeron a $11.770.482 desde $15.578.922 en el Q1 FY2024
- El ingreso antes de impuestos se convirtió en una pérdida de $931.825 desde una ganancia de $1.241.183
- El ingreso neto se convirtió en una pérdida de $675.325 desde una ganancia de $899.483
- Las ganancias por acción básicas y diluidas de las acciones comunes cayeron a ($0.76) desde $1.01
El número promedio ponderado de acciones en circulación se mantuvo estable en 894.416 para las ganancias por acción básicas y 894.405 para las ganancias por acción diluidas.
BIOQUAL, Inc. (OTC Pink: BIOQ)는 2024년 8월 31일로 종료되는 2025 회계 연도의 첫 분기 비감사 재무 결과를 발표했습니다. 회사는 지난해 같은 기간과 비교해 성과가 크게 감소했다고 보고했습니다:
- 수익은 Q1 FY2024의 $15,578,922에서 $11,770,482로 감소했습니다.
- 세전 소득은 $1,241,183의 이익에서 $931,825의 손실로 전환되었습니다.
- 순소득은 $899,483의 이익에서 $675,325의 손실로 전환되었습니다.
- 보통주 기본 및 희석 주당 수익은 $1.01에서 ($0.76)로 감소했습니다.
기본 주당 수익에 대한 가중 평균 발행 주식 수는 894,416주, 희석 주당 수익에 대한 가중 평균 발행 주식 수는 894,405주로 안정적으로 유지되었습니다.
BIOQUAL, Inc. (OTC Pink: BIOQ) a publié ses résultats financiers non audités pour le premier trimestre de l'exercice fiscal 2025, se terminant le 31 août 2024. L'entreprise a signalé une baisse significative de ses performances par rapport à la même période de l'année dernière :
- Les revenus ont diminué à $11.770.482 contre $15.578.922 au Q1 FY2024
- Le résultat avant impôts a changé pour afficher une perte de $931.825 contre un bénéfice de $1.241.183
- Le résultat net s'est transformé en perte de $675.325 contre un bénéfice de $899.483
- Le bénéfice par action de base et dilué des actions ordinaires est tombé à ($0,76) contre $1,01
Le nombre moyen pondéré d'actions en circulation est resté stable à 894.416 pour le bénéfice par action de base et à 894.405 pour le bénéfice par action dilué.
BIOQUAL, Inc. (OTC Pink: BIOQ) hat seine ungeprüften Finanzergebnisse für das erste Quartal des Geschäftsjahres 2025, das am 31. August 2024 endete, veröffentlicht. Das Unternehmen berichtete von einem signifikanten Rückgang der Leistung im Vergleich zum gleichen Zeitraum des Vorjahres:
- Der Umsatz fiel auf $11.770.482 von $15.578.922 im Q1 FY2024
- Der Gewinn vor Steuern verwandelte sich in einen Verlust von $931.825 von einem Gewinn von $1.241.183
- Der Nettogewinn war ein Verlust von $675.325 von einem Gewinn von $899.483
- Das Ergebnis je Aktie (Basis und verwässert) fiel auf ($0,76) von $1,01
Die gewogene durchschnittliche Anzahl der ausstehenden Aktien blieb stabil bei 894.416 für das Basisergebnis je Aktie und 894.405 für das verwässerte Ergebnis je Aktie.
- None.
- Revenue decreased by 24.4% year-over-year to $11.77 million
- Income before income tax turned to a loss of $931,825
- Net income shifted to a loss of $675,325
- Earnings per share declined from $1.01 to ($0.76)
|
Three Months Ended
|
||||
|
|
2024 |
|
|
2023 |
Revenue |
$ |
11,770,482 |
|
$ |
15,578,922 |
Income (Loss) Before Income Tax |
$ |
(931,825 |
) |
$ |
1,241,183 |
Net Income (Loss) |
$ |
(675,325 |
) |
$ |
899,483 |
Basic Earnings per Share of Common Stock |
$ |
(0.76 |
) |
$ |
1.01 |
Diluted Earnings per Share of Common Stock |
$ |
(0.76 |
) |
$ |
1.01 |
Weighted Average |
|||||
Number of Shares Outstanding For Basic Earnings Per Share |
894,416 |
894,416 |
|||
Weighted Average |
|||||
Number of Shares Outstanding For Diluted Earnings Per Share |
894,405 |
894,406 |
|||
For more detail related to the fiscal year 2025 unaudited first quarter results, please visit our web site at www.bioqual.com.
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241022639034/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)
Source: BIOQUAL, Inc.
FAQ
What was BIOQUAL's (BIOQ) revenue for Q1 FY2025?
How did BIOQUAL's (BIOQ) net income change in Q1 FY2025 compared to Q1 FY2024?
What was BIOQUAL's (BIOQ) earnings per share for Q1 FY2025?
How much did BIOQUAL's (BIOQ) revenue decrease in Q1 FY2025 compared to Q1 FY2024?
